| Patent application number | Description | Published |
|---|
| 20080267951 | Methods for Treating Cancer Using Agents That Inhibit Wnt16 Signaling - This invention relates to methods of inhibiting the growth of cells, in particular cancer cells that over express Wnt16 protein. The methods comprise contacting the cell with an agent that binds to Wnt16 mRNA or Wnt16 protein, interferes with Wnt16 signaling or inhibits binding of the Wnt16 protein to another protein, such as a Frizzled receptor. | 10-30-2008 |
| 20090202539 | METHOD FOR TREATING CANCER USING ANTI-WNT2 MONOCLONAL ANTIBODIES AND siRNA - This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that overexpress Wnt2. The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such as a Frizzled receptor. | 08-13-2009 |
| 20090304695 | METHODS FOR TREATING CANCER BY INHIBITING WNT SIGNALING - This invention relates to methods of inhibiting the growth of cancer cells that overexpress a Wnt protein. The methods comprise contacting the cell with an agent that inhibits binding of the Wnt protein to a Frizzled receptor. | 12-10-2009 |
| 20100233703 | EMX2 IN CANCER DIAGNOSIS AND PROGNOSIS - The present invention provides methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. The methods generally involve determining a normalized expression level of an EMX2 gene product, which correlates with prognosis and likelihood of survival. | 09-16-2010 |
| 20100240035 | MULTIGENE PROGNOSTIC ASSAY FOR LUNG CANCER - The present invention provides methods for providing a prognosis for lung adenocarcinoma, using a panel of eight molecular markers that are differentially expressed in lung adenocarcinoma. | 09-23-2010 |
| 20100292162 | SOCS-3 PROMOTER METHYLATION IN CANCER - This invention provides compositions and methods for the diagnosis and treatment of cancers that exhibit decreased SOCS-3 expression. | 11-18-2010 |
| 20110160263 | Small molecule inhibition of PDZ-domain interaction - Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general formula (I) or (III). The invention also includes combinatorial libraries, arrays and methods for screening and studying proteins using such compounds. Compounds of the invention have produced apoptosis in certain cell lines that overexpress the Dishevelled protein (Dvl), inhibiting Wnt signaling. | 06-30-2011 |
| 20110319337 | Dominant Negative WNT2 Compositions and Methods of Use - The present disclosure provides compositions, pharmaceutical preparations, kits and methods for inhibiting cell proliferation by contacting a cell expressing Fzd8 with a truncated Wnt2 polypeptide which acts as a dominant negative inhibitor of Fzd8 signaling. The present disclosure provides compositions, kits and methods for the detection of cancer by determining the level of Fzd8 and/or Wnt2 expression in a cell. | 12-29-2011 |
